TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9068464

Group type: EXPERIMENTAL
Intervention: OBTM‐2 (bismuth subcitrate 240 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 2 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: OBTM‐7 (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 1 wk)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OBTM‐2
Number of subjects: 100

Group type: COMPARATOR
Intervention: OBTM‐7
Number of subjects: 100
Study: 8453956

Group type: EXPERIMENTAL
Intervention: rac-felodipine (20 mg solution p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rac-nitrendipine (20 mg solution p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg solution p.o.)
Number of subjects: 12
Study: 29228315

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w)
Number of subjects: 336

Group type: COMPARATOR
Intervention: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w
Number of subjects: 336
Study: 27128532

Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor (22.5 mg BID for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (75 mg QD for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 30
Study: 25002300

Group type: EXPERIMENTAL
Intervention: Text message reminders about advice for dispensing artemether-lumefantrine (AL)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Standard dispensing practices without text message reminders
Number of subjects: 904
Study: 22623230

Group type: EXPERIMENTAL
Intervention: 1 g of omega-3 ethyl esters for 1 month
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 63
Study: 20736987

Group type: EXPERIMENTAL
Intervention: Controlled diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotic preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synbiotic preparation
Number of subjects: 0
Study: 19353351

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate combination (SFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 15716083

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day (administered bid)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Adverse events related to levetiracetam
Number of subjects: 99
Study: 12830369

Group type: EXPERIMENTAL
Intervention: 1 mg ibandronate
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both ibandronate groups
Number of subjects: 73
Study: 11154059

Group type: EXPERIMENTAL
Intervention: Laser acupuncture treatment
Number of subjects: 330

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 330
Study: 8878586

Group type: EXPERIMENTAL
Intervention: 250 micrograms of hypericin (H)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 526 micrograms of pseudohypericin (PH)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 750 micrograms of hypericin (H)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,578 micrograms of pseudohypericin (PH)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral administration of hypericin and pseudohypericin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Hypericum extract
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High doses of Hypericum extract
Number of subjects: 13
Study: 1904750

Group type: EXPERIMENTAL
Intervention: 1 mg ritanserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 mg ritanserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg ritanserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6309882

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole (chronic administration)
Number of subjects: 0
Study: 31714592

Group type: EXPERIMENTAL
Intervention: TRT to postchemotherapy tumor volume (study arm)
Number of subjects: 309

Group type: COMPARATOR
Intervention: TRT to prechemotherapy tumor volume (control arm)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Study arm (TRT to postchemotherapy tumor volume)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control arm (TRT to prechemotherapy tumor volume)
Number of subjects: 309
Study: 30489326

Group type: EXPERIMENTAL
Intervention: Partial stapled hemorrhoidopexy (group 1)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Circumferential stapled hemorrhoidopexy (group 2)
Number of subjects: 300
Study: 27752830

Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 40
Study: 26720308

Group type: EXPERIMENTAL
Intervention: Intermittent ADT
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Continuous ADT
Number of subjects: 1134
Study: 24864639

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of 2% prilocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of 2% prilocaine + 8 mg of dexamethasone (2 ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1.5 mg/kg 0.5% levobupivacaine
Number of subjects: 45
Study: 22274595

Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon (PMTO)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-intervention condition
Number of subjects: 110
Study: 19619284

Group type: EXPERIMENTAL
Intervention: Life-review group intervention (8 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 0
Study: 17299059

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Open-label adalimumab 40 mg every other week
Number of subjects: 276
Study: 15214257

Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour (3 g of lysine per kilogram for three months)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Wheat flour without fortification
Number of subjects: 264
Study: 11225566

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 10
Study: 10223239

Group type: EXPERIMENTAL
Intervention: C + D + T (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2, Tamoxifen 20 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: C + D (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: C + D + T
Number of subjects: 56

Group type: COMPARATOR
Intervention: C + D
Number of subjects: 56
Study: 8536512

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme substitution preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2571460

Group type: EXPERIMENTAL
Intervention: Continuous infusion of vecuronium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hourly boluses of vecuronium
Number of subjects: 12
Study: 1069595

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus BCG
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 44
Study: 29458056

Group type: EXPERIMENTAL
Intervention: Light or moderate alcohol consumption (≤1 drink/day for women and 1 to 2 drinks/day for men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy drinking (>4 drinks/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red wine consumption before or during the evening meal
Number of subjects: 0
Study: 27587469

Group type: EXPERIMENTAL
Intervention: Cryoablation + ipilimumab
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ipilimumab (single-dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 18
Study: 24657311

Group type: EXPERIMENTAL
Intervention: Chemical imbalance test feedback (bogus biological test results)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving chemical imbalance test feedback)
Number of subjects: 0
Study: 22875102

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 21077567

Group type: EXPERIMENTAL
Intervention: Alerts to left‐turn encroachment incidents
Number of subjects: 36
Study: 18690838

Group type: EXPERIMENTAL
Intervention: EGb 761 120mg bid
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2854
Study: 16330887

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI)
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) after 2-3 years of tamoxifen
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Continuing aromatase inhibitors (AI) after 5 years of tamoxifen
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Hypothetical unrestricted label for AI
Number of subjects: 16000
Study: 11881981

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg single-dose and 12 days repeated-dose)
Number of subjects: 20
Study: 9662319

Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter/intravaginal dinoprostone 4 mg every 4 hours
Number of subjects: 127

Group type: COMPARATOR
Intervention: Intravaginal misoprostol 25 microg every 4 hours
Number of subjects: 127
Study: 8148679

Group type: EXPERIMENTAL
Intervention: Self monitoring of peak flow
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with existing peak flow meters
Number of subjects: 0
Study: 3342655

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxemia (SaO2 80%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: SaO2 85%
Number of subjects: 20

Group type: COMPARATOR
Intervention: SaO2 90%
Number of subjects: 20
Study: 2254832

Group type: EXPERIMENTAL
Intervention: Experimental teeth (supragingival plaque removed)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control teeth (supragingival plaque not removed)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comparison between control and experimental teeth
Number of subjects: 2
Study: 947510

Group type: EXPERIMENTAL
Intervention: Weekly combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Intermittent combination of the same five drugs given in courses of 5 days repeated every 4 weeks
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Adriamycin as a single agent every 3 weeks
Number of subjects: 283
Study: 31599746

Group type: EXPERIMENTAL
Intervention: DAPT group (continued DAPT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Aspirin group (discontinued thienopyridines for 1 week)
Number of subjects: 87
Study: 28369670

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) program (n = 766)
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Health education program (n = 769)
Number of subjects: 1535
Study: 25627357

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 458
Study: 23774986

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 201
Study: 21148266

Group type: EXPERIMENTAL
Intervention: Unilateral long-term standardized resistance training (RES(O), n = 11)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance training with simultaneous electro-stimulation (RES(E), n = 11, 100 Hz, biphasic symmetrical wave, 400 µs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON, n = 14)
Number of subjects: 36
Study: 20301883

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (25 mg/day for 20 days) in Group A (smoking patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (25 mg/day for 20 days) in Group B (non-smoking patients)
Number of subjects: 23
Study: 17940723

Group type: COMPARATOR
Intervention: Treatment slowing atrophy rate by 30%
Number of subjects: 33
Study: 14996869

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Histological evaluation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinical outcomes
Number of subjects: 80
Study: 11435237

Group type: EXPERIMENTAL
Intervention: APRV (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PCV (n = 15)
Number of subjects: 30
Study: 9736234

Group type: COMPARATOR
Intervention: Conventional management at a hospital ward
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Treatment partly in a training apartment with problem-based education and special therapeutic support
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both management regimens (Conventional and Training Apartment)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with poor glycaemic control (mean HbA1c >8.3%)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Psychosocial risk factors (fathers' emotional responses)
Number of subjects: 38
Study: 7518982

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 48
Study: 3190970

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 75 mg kg‐1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 25 mg kg‐1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg kg‐1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg kg‐1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4-0.5 mg kg‐1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (all doses)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Midazolam (all doses)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: All doses of both premedicants
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Chloral hydrate and midazolam
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 248
Study: 31515843

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of 1.5 g of cefuroxime
Number of subjects: 18

Group type: COMPARATOR
Intervention: Short-term infusion (STI) of 1.5 g of cefuroxime
Number of subjects: 18
Study: 28108059

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Group Therapy (CBGT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 108
Study: 26077459

Group type: EXPERIMENTAL
Intervention: Therapeutic regimen of Traditional Chinese Medicine (TCM) rehabilitation
Number of subjects: 416

Group type: COMPARATOR
Intervention: Cognitive training (CT) control group
Number of subjects: 416
Study: 23528400

Group type: EXPERIMENTAL
Intervention: Licopid as immunocorrective agent
Number of subjects: 76

Group type: COMPARATOR
Intervention: Antifungal and antimicrobial treatment, eubiotics and bacteriophages
Number of subjects: 76
Study: 21782514

Group type: EXPERIMENTAL
Intervention: Letrozole for 5 days followed by HMG
Number of subjects: 53

Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 53
Study: 19307034

Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy x 1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Multiple-fraction radiotherapy (3 Gy x 10)
Number of subjects: 180
Study: 16685010

Group type: EXPERIMENTAL
Intervention: Formoterol, 9 microg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Terbutaline, 0.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15281978

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (Gore‐Tex) suture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Braided polyester (Ethibond) suture
Number of subjects: 30
Study: 11693252

Group type: EXPERIMENTAL
Intervention: Old skills executed in the context of a new task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in task complexity from training to transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative change in task complexity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response times in transfer tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance accuracy
Number of subjects: 0
Study: 9130381

Group type: EXPERIMENTAL
Intervention: Intensive family preservation services (experimental group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no intensive family preservation services)
Number of subjects: 134
Study: 8189174

Group type: EXPERIMENTAL
Intervention: Mammography only
Number of subjects: 3726

Group type: COMPARATOR
Intervention: Mammography plus EPIC study
Number of subjects: 3726
Study: 3332610

Group type: EXPERIMENTAL
Intervention: Bromocriptine at doses up to 20 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29219954

Group type: EXPERIMENTAL
Intervention: Implantation of STARFlex devices for PFO closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 27287699

Group type: COMPARATOR
Intervention: Alirocumab 150 mg every 4 weeks plus placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 4 weeks plus ezetimibe
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 4 weeks plus fenofibrate
Number of subjects: 24
Study: 24509204

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Number of subjects: 21
Study: 22440981

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20308876

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 175
Study: 18382839

Group type: EXPERIMENTAL
Intervention: School-based program intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Early intervention classrooms
Number of subjects: 76
Study: 16022756

Group type: EXPERIMENTAL
Intervention: Fermented soya milk (40 mg isoflavone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fermented soya milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-fermented soya milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increasing isoflavone dosage
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modest dosage (20-30 mg/d)
Number of subjects: 16
Study: 14727988

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day (capsules)
Number of subjects: 7098

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 160 mg once daily (tablet)
Number of subjects: 7098

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (tablet and capsule formulations)
Number of subjects: 7098

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 7098
Study: 10407838

Group type: EXPERIMENTAL
Intervention: Schizophrenic thought disorder (productive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenic thought disorder (negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borderline thought disorder
Number of subjects: 0
Study: 7781149

Group type: EXPERIMENTAL
Intervention: Oral trofosfamide, escalated doses every 3rd week until grade 2 leukopenia
Number of subjects: 23
Study: 2281055

Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (0.3 mg/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline inhalation
Number of subjects: 10
Study: 443080

Group type: EXPERIMENTAL
Intervention: 0.5 microgram of 1,25-dihydroxycholecalciferol per day for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 microgram of 25-hydroxycholecalciferol per day for 10 days
Number of subjects: 12
Study: 31503309

Group type: EXPERIMENTAL
Intervention: Multicomponent home-based physical therapy intervention (training)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Active control (transcutaneous electrical nerve stimulation and active range-of-motion exercises)
Number of subjects: 210
Study: 28911357

Group type: EXPERIMENTAL
Intervention: Combination intervention package to improve early initiation of ART and anti-tuberculosis treatment success
Number of subjects: 1233
Study: 27106971

Group type: EXPERIMENTAL
Intervention: McGrath™
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: C‐MAC™ D‐blade
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: KingVision™
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: GlideScope™
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: A.P. Advance™ difficult airway blade
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Overall success, laryngeal view, and intubation times
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Side-effects
Number of subjects: 720
Study: 24848522

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Sham auricular acupressure (Sham-AA)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 305
Study: 22352745

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 99

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 99
Study: 21336014

Group type: EXPERIMENTAL
Intervention: Ventilator circuits changed every 14 days (experimental group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ventilator circuits changed every 7 days (control group)
Number of subjects: 79